CN102688202B - 一种替莫唑胺冻干制剂 - Google Patents
一种替莫唑胺冻干制剂 Download PDFInfo
- Publication number
- CN102688202B CN102688202B CN 201210185555 CN201210185555A CN102688202B CN 102688202 B CN102688202 B CN 102688202B CN 201210185555 CN201210185555 CN 201210185555 CN 201210185555 A CN201210185555 A CN 201210185555A CN 102688202 B CN102688202 B CN 102688202B
- Authority
- CN
- China
- Prior art keywords
- temozolomide
- preparation
- freeze
- solution
- dried preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 title claims abstract description 43
- 229960004964 temozolomide Drugs 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 239000002904 solvent Substances 0.000 claims abstract description 15
- XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 claims abstract description 5
- 108010087823 glycyltyrosine Proteins 0.000 claims abstract description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims abstract description 4
- 108010044940 alanylglutamine Proteins 0.000 claims abstract description 4
- 238000009472 formulation Methods 0.000 claims description 12
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 claims description 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000003704 aspartic acid Nutrition 0.000 claims description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims description 4
- 108010010147 glycylglutamine Proteins 0.000 claims description 4
- 229960003104 ornithine Drugs 0.000 claims description 4
- KLFWVRQACSYLOH-WCCKRBBISA-N (2s)-5-amino-2-[(2-aminoacetyl)amino]-5-oxopentanoic acid;hydrate Chemical compound O.NCC(=O)N[C@H](C(O)=O)CCC(N)=O KLFWVRQACSYLOH-WCCKRBBISA-N 0.000 abstract 1
- IXUZXIMQZIMPSQ-ZBRNBAAYSA-N [(4s)-4-amino-4-carboxybutyl]azanium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound OC(=O)[C@@H](N)CCC[NH3+].[O-]C(=O)[C@@H](N)CC(O)=O IXUZXIMQZIMPSQ-ZBRNBAAYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 108010049063 ornithylaspartate Proteins 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- 238000005352 clarification Methods 0.000 description 9
- 238000004108 freeze drying Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 229940090044 injection Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 4
- 108010016626 Dipeptides Proteins 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229940011406 temozolomide injection Drugs 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940061353 temodar Drugs 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种替莫唑胺冻干制剂，含有替莫唑胺活性成分，和至少一种足以溶解替莫唑胺的增溶剂。本发明中采取的增溶剂选自N(2)-L-丙氨酰-L-谷氨酰胺、甘氨酰谷氨酰胺、甘氨酰酪氨酸、门冬氨酸鸟氨酸或它们的混合物。采用本发明技术制备的替莫唑胺制剂，更好的增加了替莫唑胺的溶解性和溶液的稳定性，质量更稳定，使用更方便，而且制备方法简单，适合大规模生产。
Description
技术领域
本发明涉及的是一种替莫唑胺冻干制剂，属于药物制剂工艺技术领域。
背景技术
替莫唑胺(Temozolomide，商品名Temodar)化学名3，4-二氢-3-甲基-4-氧代咪唑并[5，1-d]-1，2，3，5-四嗪-8-酰胺，由Schering-Plough公司开发。1999年FDA批准其口服胶囊制剂，用于治疗成人胶质细胞瘤和黑色素瘤，特别是多形性胶质母细胞瘤或间变性星形细胞瘤的一线治疗。替莫唑胺的出现是治疗恶性神经胶质瘤的一大进展。
目前临床上只有口服替莫唑胺胶囊，虽然口服后完全吸收，生物利用度高，组织分布好，可透过血脑屏障，但其副作用恶心、呕吐、头痛和倦怠的发生率非常高，重度恶心和呕吐的发病率分别为10％和6％。由于恶心、呕吐造成药物吸收不全，通常在服药前要先服用止吐药，给患者带来极大的痛苦和经济负担，另外手术后病人常不适用固体药物，再加上传统临床用药习惯，替莫唑胺注射剂更适于临床使用。
替莫唑胺在水中微溶，在甲醇中极微溶解，在乙醇、丙酮或氯仿中几乎不溶，这一特性给替莫唑胺注射剂制备带来了很大的难度。
目前对替莫唑胺注射制剂的已公开的研究文献报道如下：
US6251886中公开了一种以微粒化的悬浮液形式给药的替莫唑胺注射剂，但会导致血管堵塞，是不理想的。
中国专利CN200510014962.3中公开了一种替莫唑胺冻干粉针剂，该制剂通过调节pH和加热超声使替莫唑胺溶解，但整个溶解配制过程时间长，替莫唑胺溶液不稳定，注射剂的使用存在质量安全隐患。
中国专利CN03804363.7中公开了一种替莫唑胺冻干粉针剂，该制剂含有替莫唑胺，以及至少一种足以溶解替莫唑胺的增溶剂，所述的增溶剂是脲、L-组氨酸，L-苏氨酸、天冬酰胺酸、丝氨酸、谷氨酰胺或它们的混合物。该冻干制剂方法缩短了替莫唑胺的溶解时间和增加了溶液的稳定性，但该制备方法存在溶解后形成的溶液还是易于析出固体，专利采用二次过滤的方法来解决此问题，但这种方法存在生产时间长、操作繁琐、造成主药浪费等诸多缺点，工业化生产难以实现。
发明内容
本发明的目的是提供一种或多种更好的增溶剂，增加替莫唑胺的溶解性和溶液的稳定性，克服现有技术的不足之处，提供一种替莫唑胺冻干制剂。采用本发明技术制备的替莫唑胺冻干制剂，质量更稳定，临床使用方便，而且制备方法简单，适合大规模生产。
本发明选用一种或多种二肽做为增溶剂，增加了替莫唑胺的溶解性和溶液的稳定性。二肽优选N(2)-L-丙氨酰-L-谷氨酰胺、甘氨酰谷氨酰胺、甘氨酰酪氨酸、门冬氨酸鸟氨酸或它们的混合物。实验证明，用二肽做增溶剂，溶解后形成的溶液稳定性好，不易析出晶体，溶液澄清。采用二肽做增溶剂，溶液稳定性好，减少了生产中二次过滤的步骤，缩短了生产时间，更利于制剂的工业化生产。
本发明提供的替莫唑胺冻干制剂，含有替莫唑胺活性成分，和至少一种足以溶解替莫唑胺的增溶剂。本发明中采取的增溶剂选自N(2)-L-丙氨酰-L-谷氨酰胺、甘氨酰谷氨酰胺、甘氨酰酪氨酸、门冬氨酸鸟氨酸或它们的混合物。其中替莫唑胺活性成分的重量百分比为1～50％。增溶剂的重量百分比为2～60％。
本发明提供的替莫唑胺冻干制剂，还包含至少一种赋形剂。本发明中采取的赋形剂选自聚山梨醇酯-20、聚山梨醇酯-80、聚乙二醇、丙二醇或它们的混合物，重量百分比为1～50％。
本发明提供的替莫唑胺冻干制剂，还包含至少一种填充剂。本发明中采取的填充剂选自甘露糖醇、海藻糖、右旋糖、乳糖、甘氨酸、蔗糖、羟乙基淀粉、纤维素、环糊精、氯化钠、淀粉或它们的混合物，重量百分比为20～80％。
本发明提供的替莫唑胺冻干制剂，还包含至少一种缓冲剂。本发明中采取的缓冲剂选自柠檬酸盐水合物或它们的混合物，重量百分比为5～60％。
本发明提供的替莫唑胺冻干制剂，还包含至少一种pH调节剂，选自盐酸、磷酸、乳酸、氢氧化钠、琥珀酸、柠檬酸、酒石酸或它们的混合物，重量百分比为1～20％。
本发明提供的替莫唑胺冻干制剂，还包含到水性稀释剂，选自水、生理盐水、5％的右旋糖溶液和它们的混合物。
本发明的替莫唑胺冻干制剂的制备方法，包括下列步骤，(1)先将增溶剂、赋形剂、填充剂、缓冲剂和pH调节剂完全溶于注射用水，再将替莫唑胺溶于其中，调节pH至3.0～6.0；(2)除菌过滤、灌装，冷冻干燥形成一种冻干制剂。
具体实施方式
下面通过实施例来进一步说明本发明，但本发明的内容完全不局限于些。
实施例1
制剂组成：
制备方法：
称取上述重量的N(2)-L-丙氨酰-L-谷氨酰胺、聚山梨酯80、甘露醇、枸橼酸钠、盐酸，加入8000ml注射用水中，搅拌至固体全部溶解澄清，加入处方量的替莫唑胺，搅拌至固体全部溶解澄清，用盐酸溶液或氢氧化钠溶液调节pH到5.0；加注射用水补足体积到10000ml，经0.22μm微孔滤膜除菌过滤，分装于30ml西林瓶中，每支分装10ml溶液，放于冻干箱，冷冻干燥形成一种冻干制剂。
实施例2
制剂组成：
制备方法：
称取上述重量的甘氨酰谷氨酰胺、聚山梨酯80、甘露醇、枸橼酸钠、盐酸，加入8000ml注射用水中，搅拌至固体全部溶解澄清，加入处方量的替莫唑胺，搅拌至固体全部溶解澄清，用盐酸溶液或氢氧化钠溶液调节pH到5.0；加注射用水补足体积到10000ml，经0.22μm微孔滤膜除菌过滤，分装于30ml西林瓶中，每支分装10ml溶液，放于冻干箱，冷冻干燥形成一种冻干制剂。
实施例3
制剂组成：
制备方法：
称取上述重量的甘氨酰酪氨酸、聚山梨酯80、甘露醇、枸橼酸钠、盐酸，加入8000ml注射用水中，搅拌至固体全部溶解澄清，加入处方量的替莫唑胺，搅拌至固体全部溶解澄清，用盐酸溶液或氢氧化钠溶液调节pH到5.0；加注射用水补足体积到10000ml，经0.22μm微孔滤膜除菌过滤，分装于30ml西林瓶中，每支分装10ml溶液，放于冻干箱，冷冻干燥形成一种冻干制剂。
实施例4
制剂组成：
制备方法：
称取上述重量的门冬氨酸鸟氨酸、聚山梨酯80、甘露醇、枸橼酸钠、盐酸，加入8000ml注射用水中，搅拌至固体全部溶解澄清，加入处方量的替莫唑胺，搅拌至固体全部溶解澄清，用盐酸溶液或氢氧化钠溶液调节pH到5.0；加注射用水补足体积到10000ml，经0.22μm微孔滤膜除菌过滤，分装于30ml西林瓶中，每支分装10ml溶液，放于冻干箱，冷冻干燥形成一种冻干制剂。
实施例5
考察实施例1～4制备的冻干制剂样品的稳定性。
实验条件：(25℃±2℃，RH60％±10％)
考察项目：有关物质、含量
测定频率：第0、3、6、9、12、18、24个月末取样测定
考察方法：参照中国药典2010版二部标准，
有关物质：采用高效液相色谱法，1％自身对照法测定
含量：采用高效液相色谱法，外标法测定
考察结论：实施例1～4制备的冻干制剂样品，在放置24个月后，含量和有关物质均未发生明显变化，说明实施例1～4制备的冻干制剂样品稳定性可靠。具体实验结果下表1。
表1实施例1～4冻干制剂样品中的稳定性实验结果
Claims (3)
1.一种替莫唑胺冻干制剂，含有替莫唑胺活性成分、和至少一种足以溶解替莫唑胺的增溶剂，增溶剂选自N(2)-L-丙氨酰-L-谷氨酰胺、甘氨酰谷氨酰胺、甘氨酰酪氨酸、门冬氨酸鸟氨酸或它们的混合物。
2.如权利要求1所述的冻干制剂，其特征在于，替莫唑胺活性成分的重量百分比为1～50％。
3.如权利要求1所述的冻干制剂，其特征在于，增溶剂的重量百分比为2～60％。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210185555 CN102688202B (zh) | 2012-06-07 | 2012-06-07 | 一种替莫唑胺冻干制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210185555 CN102688202B (zh) | 2012-06-07 | 2012-06-07 | 一种替莫唑胺冻干制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102688202A CN102688202A (zh) | 2012-09-26 |
| CN102688202B true CN102688202B (zh) | 2013-08-14 |
Family
ID=46854051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210185555 Active CN102688202B (zh) | 2012-06-07 | 2012-06-07 | 一种替莫唑胺冻干制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102688202B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103845294A (zh) * | 2012-12-03 | 2014-06-11 | 杭州容立医药科技有限公司 | 替莫唑胺注射用粉针制剂和制备方法 |
| CN104274412A (zh) * | 2013-07-01 | 2015-01-14 | 北京恒瑞康达医药科技发展有限公司 | 一种含有替莫唑胺、其药学上可接受的盐或其他衍生物的药物制剂 |
| CN104721155B (zh) * | 2015-04-07 | 2017-09-29 | 齐鲁制药(海南)有限公司 | 一种替莫唑胺冻干粉制剂及其制备方法 |
| CN107619428B (zh) * | 2017-09-22 | 2020-08-28 | 南京优科生物医药研究有限公司 | 鸟氨酸与门冬氨酸二肽化合物的酰化衍生物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2476494C (en) * | 2002-02-22 | 2010-04-27 | Schering Corporation | Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same |
| CN101869551B (zh) * | 2010-06-28 | 2012-04-18 | 江苏奥赛康药业股份有限公司 | 一种替莫唑胺冻干制剂 |
| CN101984968A (zh) * | 2010-10-29 | 2011-03-16 | 北京润德康医药技术有限公司 | 抗肿瘤剂替莫唑胺的药物制剂制备方法 |
-
2012
- 2012-06-07 CN CN 201210185555 patent/CN102688202B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102688202A (zh) | 2012-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104922145B (zh) | γ-氨基丁酸与壳寡糖的组合物及其制备方法和应用 | |
| CN102688202B (zh) | 一种替莫唑胺冻干制剂 | |
| NO335045B1 (no) | Farmasøytiske formuleringer av temozolomid, fremgangsmåter for fremstilling av disse, lyofilisert pulver av formuleringene, fremstilt artikkel inneholdende det lyofiliserte pulveret, og anvendelse av formuleringene som medikament | |
| CN101984968A (zh) | 抗肿瘤剂替莫唑胺的药物制剂制备方法 | |
| JP2014533251A (ja) | メラトニンベースの溶液およびそれらの製造のための粉末 | |
| WO2008086698A1 (fr) | Forme injectable de forsythoside et préparation de celle-ci | |
| CN102342931B (zh) | 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法 | |
| CN104922143B (zh) | Egcg与壳寡糖的组合物及其制备方法和应用 | |
| CN106137985A (zh) | 一种稳定的棕榈酸帕利哌酮长效制剂 | |
| CN102335114B (zh) | 一种稳定的布洛芬精氨酸注射剂及其制备方法 | |
| CN104840800A (zh) | 竹叶黄酮与γ-氨基丁酸的组合物及其制备方法和应用 | |
| CN105125505B (zh) | 注射用盐酸托烷司琼冻干粉针及其制备方法 | |
| CN104274412A (zh) | 一种含有替莫唑胺、其药学上可接受的盐或其他衍生物的药物制剂 | |
| BR112018074655B1 (pt) | Formulação injetável de fosnetupitanto, método de fabricação de uma formulação e uso de uma formulação injetável | |
| CN103432085A (zh) | 一种含氨基酸增溶剂的替莫唑胺冻干制剂及其制备方法 | |
| CN103432086B (zh) | 一种注射用培美曲塞二钠冻干粉针剂及其制备方法 | |
| CN105641701A (zh) | 一种稳定的制霉菌素药物组合物及其制备方法 | |
| CN106890146A (zh) | 一种磷酸奥司他韦分散片及其制备方法 | |
| CN105147664B (zh) | 葛根素注射液及制备方法 | |
| CN104739776A (zh) | 左卡尼汀的固体分散体组合物及其制备方法和药物应用 | |
| TWI619716B (zh) | 含維生素ｃ或其衍生物的替莫唑胺醫藥組成物及其製備方法 | |
| CN102552283B (zh) | 皮肤用含有辅料的丁酸氢化可的松与含有辅料的水的透皮吸收药物 | |
| CN106937944A (zh) | 一种注射用甲硝唑冻干粉针制剂及其制备方法 | |
| US11576929B2 (en) | Composition for inflammatory gastrointestinal disorders | |
| CN107184548A (zh) | 一种安全性高的左旋奥硝唑注射液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder |
Address after: 100101 No. 2 building, No. 19, Beiyuan East Road, 2508, Beijing, Chaoyang District, 25 Patentee after: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Address before: 100101 Beijing Chaoyang District Anli Road, Sunshine Plaza, No. 68 room C1-802 Patentee before: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. |
|
| CP02 | Change in the address of a patent holder | ||
| DD01 | Delivery of document by public notice |
Addressee: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Wen Ying Document name: Notification of Passing Examination on Formalities |
|
| DD01 | Delivery of document by public notice | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Temozolomide freeze-dried preparation Effective date of registration: 20180705 Granted publication date: 20130814 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: 2018990000537 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20181107 Granted publication date: 20130814 Pledgee: Beijing first financing Company limited by guarantee Pledgor: BEIJING LUNARSUN PHARMACEUTICAL Co.,Ltd. Registration number: 2018990000537 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200818 Address after: D3-8-2, Erlang international student Pioneer Park, 71-1, Kecheng Road, Jiulongpo District, Chongqing Patentee after: Chongqing Shisen Pharmaceutical Technology Co.,Ltd. Address before: 100101 No. 2 building, No. 19, Beiyuan East Road, 2508, Beijing, Chaoyang District, 25 Patentee before: Beijing Lunarsun Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A freeze-dried preparation of temozolomide Effective date of registration: 20231008 Granted publication date: 20130814 Pledgee: Bank of China Limited Chongqing Jiulongpo Branch Pledgor: Chongqing Shisen Pharmaceutical Technology Co.,Ltd. Registration number: Y2023500000079 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |